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embolismand blood. Chemotherapy was started with cefazolin, followed by combination therapy with
meropenem/vancomycin with surgery. The MSSA (strain KS1) was positive for increased levels
of cytolytic peptide (psma and hld ) and staphylococcal enterotoxin B (SEB), and manifested
IS1216V-mediated multidrug resistance (to erythromycin, clindamycin, kanamycin, strepto-
mycin, and chloramphenicol), similar to a genome-analyzed reference strain (PM1) of ST59/
SCCmecV(5C2&5) community-associated methicillin-resistant S. aureus (Taiwan CA-MRSA),
but unlike another reference strain (M013) of Taiwan CA-MRSA in terms of resistance. The data
suggest that CA-MSSA KS1, characterized by PVL, increased levels of cytolytic peptide, SEB,
and multidrug resistance, is a possible ancestral strain of Taiwan CA-MRSA and causes the un-
ique association of osteomyelitis and septic pulmonary embolism, requiring complicated man-
agement.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Although methicillin-resistant Staphylococcus aureus
(MRSA) is a major nosocomial pathogen, known as
healthcare-associated MRSA (HA-MRSA), MRSA has also been
isolated in the community since 1997e1999 and is known as
community-associated MRSA (CA-MRSA).1 CA-MRSA exhibits
increased expression of cytolytic peptide [or phenol-soluble
modulin (PSM)] genes and often produces Panton-Valentine
leukocidin (PVL).2,3 The most characterized PVL-positive
(PVLþ) CA-MRSA includes four clones: multilocus sequence
type 8 (ST8)/staphylococcal cassette chromosome mec
type IV (SCCmecIV), known as USA300; ST30/SCCmecIV;
ST80/SCCmecIV; and ST59/SCCmecV, known as the Taiwan
clone.3,4 Other characteristics unique to each clone are the
arginine catabolic mobile element (ACME) for USA3003; and
for the Taiwan CA-MRSA clone, staphylococcal enterotoxin
B (SEB) and multidrug resistance (to erythromycin, clinda-
mycin, kanamycin, streptomycin, chloramphenicol, and
tetracycline), encoded by the enterococcal IS1216V-asso-
ciated mobile element structure (MESPM1) and MEStet.
4,5
Osteomyelitis is an invasive infection mostly caused by
S. aureus, and with inappropriate treatment, it can be a
devastating or even fatal disease.6 In the United States,
where USA300 is the predominant CA-MRSA,3 MRSA osteo-
myelitis cases, occasionally complicated with septic pul-
monary embolism, have increased.7,8 Moreover, USA300-
type CA-MSSA, which lacks SCCmec, accounts for a
growing proportion (around 25%) of CA-MSSA and is associ-
ated with increased cases of pediatric invasive CA-MSSA
infections, especially osteomyelitis.8 Here, we describe
the unique association of osteomyelitis and septic pulmo-
nary embolism due to PVLþ CA-MSSA related to the Taiwan
CA-MRSA clone, which required complicated management.
Case Report
A 15-year-old boy (baseball player) was admitted due to
fever and pain with swelling of the left femur in August
2010. He developed a furuncle accompanied by pus
discharge twice on the anterior surface of the left knee
after an insect bite, but showed improvement 15 days
before admission. On admission, body temperature was
39.0C, white blood cell (WBC) count was 18,600/mL,platelet count was 185,000/mL, C-reactive protein (CRP)
was 16.8 mg/dL, and the erythrocyte sedimentation rate
(ESR) was 67 mm/hour. Pyomyositis in the vastus inter-
medius and abscesses in the subperiosteal area were noted
on the left lower thigh, and also inflammation spreading to
the bone marrow (osteomyelitis) was suspected on mag-
netic resonance imaging (MRI, Fig. 1A). Incision and pus
drainage were performed, and the administration of cefa-
zolin (3 g/day) was initiated. Cultures of blood and pus,
obtained from the subperiosteal area of the femur,
revealed PVLþ MSSA. In spite of cefazolin administration at
high doses, dyspnea gradually developed on Day 5, with
continuous hyperthermia ( 39C) and with no improve-
ment of his laboratory data (CRP, 15.6 mg/dL; WBC, 8300/
mL). A diagnosis of septic pulmonary embolism was made on
Day 5, based on contrast-enhanced computer-assisted to-
mography (CT) findings (Fig. 1B). A CT scan also showed
posterior pleural and pulmonary infiltrates (Fig. 1B), sug-
gesting pneumonia. Cefazolin was changed to meropenem
(2 g/day) according to the Japanese guidelines for hospital-
acquired pneumonia,9 because the possibility that his res-
piratory disturbance was caused by pneumonia could not be
ruled out. On Day 8, hyperthermia ( 38C) continued
despite some improvement of his laboratory data (CRP,
9.8 mg/dL; ESR, 88 mm/hour; WBC, 13,500/mL). Left
femoral osteomyelitis was still noted, and femoral fenes-
tration and drainage were performed. Vancomycin (1 g/
day) was added for possible MRSA infection. Dyspnea
improved on Day 10 and clinically improved on Day 15: body
temperature, 36.8C; CRP, 0.3 mg/dL; ESR, 30 mm/hour;
WBC count, 4800/mL; and platelet count, 256,000/mL.
Based on clinical effectiveness, the administration of
meropenem (for a further 2 weeks) and vancomycin (for a
further 3 weeks) was continued; due to his unstable tem-
perature (occasionally > 37C), this was followed by oral
cloxacillin for 6 weeks. He was discharged on Day 76. No
MRSA was isolated throughout his clinical course.
The pus MSSA isolatewas designated as KS1 andmolecular
characterizations were performed as described previ-
ously.5,10,11 Briefly, multilocus sequence typing (MLST) was
performed using seven housekeeping genes, and an allelic
profile (allele no.; ST type) was obtained from the MLST
website (http://www.mlst.net/). The spa typewas analyzed
using a polymerase chain reaction (PCR) [targeting the spa
(protein A) gene], and determined using a public spa-type
Figure 1. Left femoral osteomyelitis complicated by septic pulmonary embolism in a 15-year-old boy (baseball player). In (A),
showing lower limb magnetic resonance imaging (MRI), high-intensity regions were noted in the (intermediate vastus) muscle
around the distal end of the left femur on fat-suppressed T2-weighted imaging (pyomyositis, large arrows; subperiosteal abscess,
small arrows), and the bone marrow was accompanied by high-intensity regions and weak enhancement (inflammation of the bone,
arrowheads). In (B), chest computer-assisted tomography (CT) showed bilateral multiple foci of consolidations (septic embolism,
arrows), with pleural effusion and pulmonary infiltrate (pneumonia, arrowheads) at the posterior.
PVLþ ST59 CA-MSSA from osteomyelitis 567database (http://tools.egenomics.com/) or Ridom Spa-
Server (http://spaserver.ridom.de/). Typing of agr was
carried out by PCR and the agr-variable region was
sequenced as previously described.12 Coagulase (Coa) typing
was conducted using a staphylococcal Coa antiserum kit
(Denka Seiken, Tokyo, Japan). Virulence genes were
analyzed by PCR11,13; the target genes in PCR included 50
genes: three leukocidin genes (lukPVSF, lukE-lukD, and
lukM ), five hemolysin genes (hla, hlb, hlg, hlg-v, and hld ), a
peptide cytolysin (psma), 19 SE genes (tst, sea, seb, sec, sed,
see, seg, seh, sei, sej, sek, sel, sem, sen, seo, sep, seq, ser,
and set), one putative staphylococcal enterotoxin gene
(seu), three exfoliative toxin genes (eta, etb, and etd ), a
staphylococcal superantigen-like gene cluster (ssl ), the
epidermal cell differentiation inhibitor gene (edin), 14
adhesin genes (icaA, icaD, eno, fib, fnbA, fnbB, ebpS, clfA,
clfB, sdrC, sdrD, sdrE, cna, and bbp), the staphylokinase
gene (sak) carried by the innate immuneevasion cluster (IEC)
of phage 3 (4SA3), and the ACME-arcA gene. The amount of
SEB in the supernatant of bacterial cultures at 2.0 l09 CFU/
mL was examined using a SET-RPLA kit (Denka Seiken) ac-
cording to the instructions of the manufacturer. For pulsed-
field gel electrophoresis (PFGE), bacterial DNA was digestedwith SmaI, and the digested DNAwas electrophoresed in 1.2%
agarose with marker DNA (Lambda ladder; Bio-Rad Labora-
tories, Inc., Hercules, CA, USA) as described previously.12
DNA banding patterns of MSSA KS1 were compared with
those of eight strains of PVLþ ST59/SCCmecV CA-MRSA
(Taiwan clone), which included seven strains from Taiwan
(PM1, PM2, PM5, PM6, PM11, PM17, and TSGH17) and one
strain (OS7) from Japan10,12; and also with the banding pat-
terns of two strains of PVL-negative (PVLe) ST59/SCCmecIV
CA-MRSA, which included PM34 and PM36 from Taiwan.10
Susceptibility testing of bacterial strains was carried out
using the agar dilution method with Mueller-Hinton agar.14
Antimicrobial agent interactions were evaluated by agar
checkerboard tests; the fractional inhibitory concentrations
(FIC) of 0.5,> 0.5e4.0, and> 4.0 were defined as synergy,
no interaction (nonsynergic), and antagonism.15 Drug resis-
tance genes, mecA (encoding for resistance to b-lactam
agents including methicillin, oxacillin, and cephems), ermB
(encoding for erythromycin and clindamycin resistance),
aph(30)-IIIa (encoding for kanamycin resistance), aadE
(encoding for streptomycin resistance), and cat (encoding
for chloramphenicol resistance), were analyzed as previ-
ously described.5,10 The mRNA expression levels of the
568 E. Sawanobori et al.cytolytic peptide (PSMa and Hld) genes (psma and hld ) and
16S rRNA geneswere examined by reverse transcription (RT)-
PCR assay.16 The psma and hld expression levels were
normalized by the 16S rRNA expression level. The level of
significance was defined as p < 0.05.
Strain KS1 was susceptible to oxacillin [minimum inhibi-
tory concentration (MIC), 0.13 mg/mL], and negative for the
mecA gene in PCR. KS1 was also susceptible to cefazolin,
meropenem, and vancomycin; MIC values (mg/mL) were
0.25, 0.03, and 1.0, respectively. The in vitro effect of
meropenem/vancomycin combination against KS1 showed
no interaction (nonsynergistic), but hadanFICof>0.5 to 1.0.
Molecular characteristics of KS1, compared with
genome-analyzed reference strains (PM1 and M013) of the
Taiwan CA-MRSA clone, are summarized in Table 1. KS1
belongs to the genotype (ST59/spa143[t437]/agr1a/Coa VII)
and carries the genes for PVL, four hemolysins (a-hemo-
lysin, Hla; b-hemolysin, Hlb; g-hemolysin, Hlg; d-hemo-
lysin, Hld), three staphylococcal enterotoxins (SEB, SEK,
SEQ), and 11 adhesins (icaA, icaD, eno, fib, fnbA, fnbB,
ebpS, clfA, clfB, sdrC, and sdrE ), similar to the Taiwan CA-
MRSA clone, including strain PM1.5,10 The SEB production
levels of KS1 and PM1 were 15.6e31.3 mg/mL. Moreover,
similar to PM1, KS1 was resistant to five non-b-lactam
agents, erythromycin (MIC,  256 mg/mL) and clindamycin
(MIC,  256 mg/mL), kanamycin (MIC,  256 mg/mL),
streptomycin (MIC,  256 mg/mL), and chloramphenicol
(MIC, 64e128 mg/mL), and had each corresponding drug
resistance gene, ermB, aph(30)-IIIa, aadE, and cat.Table 1 Relevant characteristics of methicillin-susceptible Sta
ST59/SCCmecV CA-methicillin-resistant S. aureus (MRSA) referen
Type, virulence gene, drug resistance
gene, genetic structure, phenotype,
mutation
MSSA
Strain KS1
(PCR/sequence
data, etc.)
Type
ST 59
spa 143 (t437)
agr 1ac
SCCmec type e
Coagulase type VII
Virulence gene
Leukocidin genes
lukPVSF (PVL) þ
lukE-lukD e
Hemolysins
hla, hlb, hlg, hlg-v, hld þ
Enterotoxin
SaPI3 (seb1, sek, seq) þ (SEB, 16-32 mg/ml) g
tst, sea, sec, sed, see, seg,
see, sei, sej,
sel, sem, sen, seo, sep h,
set, seu
e
Exfoliative toxin
eta, etb, etd e
Others
psma þ (high expression)
ssl þSince strain PM1 (Taiwan CA-MRSA clone) carries the five
non-b-lactam resistance genes in a unique MES (MESPM1),
with the array of IS1216V-ermB-aph(3’)-IIIa-aadE-IS1216V-
IS1216V-cat-IS1216V-IS1216V,5 KS1 was investigated for the
presence of the MESPM1 structure by PCR and sequencing. As
expected, KS1 also possessed the same MESPM1 structure,
which was inserted into the chromosomal sasK gene with a
8-bp attachment sequence (att, consisting of tattaaat),
similar to PM1 (Fig. 2A).
The genetic relatedness of KS1 and Taiwanese CA-MRSA
was also determined by PFGE analysis (Fig. 2B). KS1 and
strains of the Taiwan CA-MRSA clone (PVLþ ST59/SCCmecV)
comprised subclusters, in which each strain differed from
others by no more than three bands, indicating a single
clone (Taiwan CA-MRSA/MSSA clone). These subclusters of
the Taiwan CA-MRSA/MSSA clone were divergent from those
of PVL- ST59/SCCmecIV CA-MRSA, another representative
CA-MRSA in Taiwan4,19 (Fig. 2B).
The expression levels of the cytolytic peptide genes
(psma and hld ) are summarized in Fig. 2C. Regarding ST59
CA-MRSA, both PVLþ/SCCmecV and PVL-/SCCmecIV (irre-
spective of PVLþ and PVL- types) expressed the psma and
hld genes at high levels, similar to USA300, but significantly
higher than HA-MRSA, ST5/SCCmecII (New York/Japan
clone) or ST239/SCCmecIII (p < 0.05). Unexpectedly, the
expression levels of one Taiwan clone strain (TSGH17)10,24
were very low; the reason remains unclear.
PVLþ CA-MSSA strain KS1 expressed the psma and hld
genes at high levels, similar to CA-MRSA. When other MSSAphylococcus aureus (MSSA) strain KS1, compared with Taiwan
ce strains PM1 and M013, whose genomes were analyzed
Taiwan ST59/SCCmecV CA-MRSA
Strain PM1
(genome dataa, etc.)
Strain M013
(genome datab)
59 59
143 (t437) 143 (t437)
1ac 1ac,d
V (5C2&5) e V (5C2&5) d,e
VII VIId
þ (4SA2PM1) f þ (phage) f
e e
þ þ
þ (SEB, 16-32 mg/ml) g þ
e e
e e
þ (high expression) þ (expression, NDi)
þ þ
Table 1 (continued )
Type, virulence gene, drug resistance
gene, genetic structure, phenotype,
mutation
MSSA Taiwan ST59/SCCmecV CA-MRSA
Strain KS1
(PCR/sequence
data, etc.)
Strain PM1
(genome dataa, etc.)
Strain M013
(genome datab)
edin e e e
sak h e e e
Adhesin
c11agj þ þ þ
(fnbA:167-bp insertion, resulting
in frame shift)
(sdrC: 24-bp deletion)
sdrD, cna, bbp e e e
ACME (arcA) e e e
Drug resistance
b-lactam resistance
mecA (MIC of oxacillin, mg/ml) e (0.125) þ (8) þ (NDi)
blaZ (ABPCr/s)/PCase
plasmid (size, kb)
- (ABPCs)/k þ (ABPCr)/pPM1 (26 kb) l NDi/NDi
Non-b-lactam resistance
MESPM1 (EM
r, CLDMr,
KMr, SMr, CPr) m
þ þ e
MEStet (TC
r) l e þl NDi
Other phage
FSA1PM1 ND
i þ e
Relevant mutation in another chromosomal gene
sasA NDi e 54-bp deletion
a Data are from a previous paper5 and GenBank Accession numbers ABFA01000000, AB699881, AB699882.
b Data are from a previous paper 17 and GenBank Accession number CP003166.
c agr1a, a variant of agr1.12
d Assigned, based on the reported sequences; a previous paper 17 and GenBank Accession number CP003166.
e SCCmecV (5C2&5), a composite type of SCCmecV; although SCCmecV (5C2) consists of type 5 ccr (ccrC ) and class C2 mec
gene complexes, SCCmecV (5C2&5) has an additional ccrC gene complex (Z type 5 ccr gene complex).18 The entire SCCmecV (5C2&5)
sequences of strains PM1 and M013 show high homology (99.8%).
f PVL phage is described in parentheses. For strain M013, the name of the PVL phage is not described; a previous paper 17 and GenBank
Accession number CP003166. The entire PVL phage sequences of strains PM1 and M013 are nearly identical (homology, > 99.9%).
g SEB production levels in vitro.
h Two genes (sep and sak) are located in the innate immune evasion cluster (IEC) of phage 3 (4SA3), which is present in PVL- ST59/
SCCmecIV CA-MRSA (in Taiwan) but absent in PVLþ ST59/SCCmecV CA-MRSA (Taiwan clone).5,17,19
i ND, not determined or not described.
j c11ag, core 11 adhesin genes shared by all strains: icaA, icaD (for biofilm formation); eno (for laminin-adhesin); fnbA, fnbB (for
fibronectin-adhesin); ebpS (for elastin-adhesin); clfA, clfB, fib, sdrC, sdrE (for fibrinogen-adhesin).
k Strain KS1 carries no plasmid.
l PCase plasmid (pPM1) of strain PM1 carries the 6-kb MEStet structure, encoding for TC resistance.
5
m A multidrug resistance structure (MESPM1), encoding for resistance to EM, CLDM, KM, SM and CP, is located within the sasK gene on the
chromosome (in strain PM1),5 as shown in Fig. 2A; the same structure was also found in strain KS1.
ABPC Z ampicillin; ACME Z arginine catabolic mobile element; CLDM Z clindamycin; CP Z chloramphenicol; EM Z erythromycin;
KM Z kanamycin; MES Z mobile element structure; MIC Z minimum inhibitory concentration; PCase Z penicillinase; PVL Z Panton-
Valentine leukocidin; r Z resistant; s Z susceptible; SaPI Z staphylococcal pathogenicity island; SCCmec Z staphylococcal cassette
chromosome mec; SEB Z staphylococcal enterotoxin B; SM Z streptomycin; ST Z sequence type; TC Z tetracycline.
PVLþ ST59 CA-MSSA from osteomyelitis 569strains were examined, the psma expression levels of PVLþ
MSSA strains isolated in the community were significantly
higher than PVL- MSSA strains isolated in hospitals (Fig. 2C).Discussion
Osteomyelitis is an infectious disease of the bones, pre-
dominantly from S. aureus, and is most often seen in chil-
dren and elderly people. In pediatric S. aureusosteomyelitis, venous thrombosis occurs with or without
the development of septic pulmonary embolism, which
results in dyspnea with hyperthermia, albeit rarely.7
In the United States, USA300 is a major cause of the
increase of osteomyelitis and also of venous thrombosis
with septic pulmonary embolism,7,8 and is associated with
pathologic fracture following osteomyelitis.25 With the
spread of USA300, pediatric osteomyelitis cases from
USA300-type MSSA have also increased.8,26 In Taiwan, pe-
diatric cases of bone/joint infections from CA-MRSA,
Figure 2. IS1216V-richmultidrug resistance structure (A), pulsed-fieldgelelectrophoresis (PFGE)patterns (B), andmRNAexpression
levels of the cytolytic peptide genes (psma and hld ) (C) of Panton-Valentine leukocidin-positive (PVLþ) ST59 CA-methicillin-
susceptible Staphylococcus aureus (MSSA) strain KS1. In (A), the structure of enterococcal IS1216V-mediated composite transposon
(named MESPM1) of the Taiwan clone [PVL
þ ST59/SCCmecV CA-methicillin-resistant S. aureus (MRSA) strain PM1] is shown at the top.
The MESPM1 is 21,832 bp long, flanked by direct repeats of IS1216V at both ends, and inserted into the att site (8-bp target sequence,
tattaaat) within the sasK gene; the MESPM1 contains three att sites (shown as a vertical red line).
5 The genes, ermB, aph(3’)-IIIa, aadE,
and cat, respectively, encode for resistance to erythromycin/clindamycin, kanamycin, streptomycin, and chloramphenicol. Vertical
arrows below theMESPM1 show the position of polymerase chain reaction (PCR) primers
5 used to identify the corresponding region (and
sequence) of strain KS1; PCR and sequence analysis revealed that KS1 possesses exactly the same mobile element structure (MES)
(MESPM1) on the chromosomewith the sameatt sequence. In (B), the PFGEpattern of KS1was comparedwith theTaiwanCA-MRSAclone
(strains PM1, PM2, PM5, PM6, PM11, PM17, TSGH17, and OS7)10,12 and Taiwanese PVL- ST59/SCCmecIV CA-MRSA (strains PM34 and
PM36).10 Isolates from Japan (OS7 and KS1) aremarked in yellow. In (C), the blue box shows themRNA expression levels of two control
MRSA groups, PVLþ CA-MRSA (which shows high expression levels) and PVL- HA-MRSA (which shows low expression levels). Strains: (for
ST8/SCCmecIV CA-MRSA, USA300) type strain USA300-0114, Japanese isolates NN3620 and NN4721; [for ST5/SCCmecII HA-MRSA, New
York/Japan (NY/J) clone] reference strains N315 and Mu50, strain I6 from Japan,22 strain PM29 from Taiwan10; (for ST239/SCCmecIII
HA-MRSA) reference strainsHU25andANS46,Taiwanese strainsPM3,PM14,PM27,andPM38,10 Russian strains 6K,8K, 14K,16K, 20K,and
51K.23 The orange box shows the data of two predominant CA-MRSA in Taiwan. Strains: (for PVLþ ST59/SCCmecV MRSA, Taiwan clone)
PM1, PM2, PM5, PM6, PM11, PM17, and TSGH17 fromTaiwan,10 OS7 from Japan12 (TSGH17with unexpectedly low expression levels was
omitted); (for PVL- ST59/SCCmecIV MRSA) PM34, PM36, PM42, and SSF17,10 laboratory stock strains 4578, 6272-2, and 8038 from
Taiwan. The green box shows the data of PVLþ and PVL- MSSA. Deep green, KS1. Strains: (for PVLþ laboratory stock MSSA) ST25, ST30,
ST50, and ST121 isolates mostly from skin soft tissue infections, such as furuncles and bullous impetigo in the community; (for PVL-
laboratory stock MSSA) isolates from blood, sputum, urinary tract discharge, and others of inpatients (probably also of outpatients).
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PVLþ ST59 CA-MSSA from osteomyelitis 571including those with septic pulmonary embolism, have been
reported19,27,28; all secondary pneumonia cases, preceded
by bone/joint infections, accompanied septic pulmonary
embolism and were considered to be caused by the Taiwan
clone (PVLþ ST59/SCCmecV) or its variant.27 This study
demonstrates the unique association of osteomyelitis and
septic pulmonary embolism from PVLþ ST59 CA-MSSA.
The patient was a young athlete (baseball player) at risk
of community-acquired infection,4 and suffered from skin
and soft-tissue infection (SSTI, furuncle) prior to osteomy-
elitis. His family members (37-year-old father, 39-year-old
mother, 13-year-old brother, and < 1-year-old sister) were
all negative for PVLþ MSSA and he had never been to
Taiwan; therefore, the origin of his MSSA infection remains
unexplained. Pyomyositis, subperiosteal abscesses, and
osteomyelitis occurred on the left femur (the most common
site of infection),6,29 and the development of septic pul-
monary embolism was an event related to bone infection.7
After discharge, he suffered from a fracture at the same
bone site as osteomyelitis. These clinical data suggest that
KS1 is a highly virulent strain.
Osteomyelitis requires prolonged chemotherapy,29,30 at
least 4e6 or 8 weeks for MRSA infection6,30 and approxi-
mately 3 weeks for MSSA infection,6 until normalization of,
for example, CRP or ESR levels.6,29,30 For osteomyelitis,
chemotherapy starts almost always empirically, and in
children, empirical treatment may start with a first-
generation cephem (cephalosporin), if the prevalence of
MSSA in the community is > 90%; with clindamycin, if the
prevalence of MRSA in the community is  10% and the
prevalence of clindamycin-resistant S. aureus is < 10%; or
with vancomycin, if the prevalence of MRSA and
clindamycin-resistant S. aureus in the community is  10%6;
the cutoffs of prevalence provided here are the personal
opinion of some authors, not conclusions from well-
designed trials.
Moreover, a protocol of safe switching from intravenous
to oral medication has been discussed positively.6 In a
clinical observation in Taiwan, linezolid was used as step-
down (oral) therapy for pediatric osteomyelitis due to
MRSA (and MSSA), producing useful and well-tolerated re-
sults.31 It has also been reported that clindamycin and
linezolid, protein-synthesis inhibitors, suppress the pro-
duction of some S. aureus toxins such as PVL in vitro.32
Another report, however, did not recommend any specific
antibiotic for PVLþ cases.33
In this case, the initial therapy with cefazolin, a first-
generation cephalosporin, was switched to intravenous
combination therapy with meropenem and vancomycin
with surgery, resulting in normalization of CRP after 9 days
in total. The reason for cefazolin’s inefficiency remains
uncertain. However, since for osteomyelitis, the response
to treatment is usually slow, in this case with an abscess in
deep-seated structures, surgical debridement with a pro-
longed course of antibiotic treatment (even with cefazolin)
could have been adequate.
Meropenem/vancomycin combination exhibits in vitro
synergic (FIC  0.5) or additive (FIC > 0.5e1) action against
ST5/SCCmecII HA-MRSA (New York/Japan clone).34 In this
study, the combination effect was synergic for ST239/
SCCmecIII, a dominant HA-MRSA clone in Taiwan (10
Taiwanese strains previously described10). However, thecombination effect showed no interaction (nonsynergic),
but had an FIC of > 0.5e1, against ST59 MSSA and MRSA,
including KS1 (and other 9 MSSA strains), ST59/SCCmecV
CA-MRSA (20 strains, including those used in Fig. 2C), and
ST59/SCCmecIV CA-MRSA (10 strains, including those used
in Fig. 2C).
Two strains of the Taiwan clone (PM15 and M01317) have
been analyzed at genome levels, and the characteristics of
KS1 were compared with those of reference strains.
Regarding the SCCmec type of the Taiwan clone, initially, it
was reported as type VT, based on the partial SCCmec
sequence of strain TGSH1724; later it was reported as
SCCmecVII,10,35 and finally reclassified as type V (5C2&5),18
based on the entire SCCmec sequence of strain PM1, and
more importantly based on the finding that the SCCmec was
a composite SCCmec carrying two ccrC genes.10,35
The Taiwan clone has been multidrug-resistant to five
non-b-lactam agents (erythromycin, clindamycin, kana-
mycin, streptomycin, and chloramphenicol), since its initial
isolation in Taiwan,4,5,10,24,36 unlike other major PVLþ CA-
MRSA.4 Non-b-lactam resistance was encoded for by a
unique mobile genetic structure MESPM1, which was rich in
IS1216V5; recombination events between IS1216V copies
within the structure could result in various drug resistance
patterns.5
IS1216V originates in enterococci.37 IS1216V was also
found in Tn1546 with the vanA gene (encoding for vanco-
mycin resistance) in vancomycin-resistant S. aureus
(VRSA)38 or in a possible composite transposon containing
Tn1546 in Enterococcus faecium.39 MESPM1 most probably
originates in enterococci.5 Occasionally, the Taiwan CA-
MRSA clone also manifests tetracycline resistance.5,10
which is encoded for by the MEStet, located on a penicil-
linase (PCase) plasmid.5
PM1 is a typical example of full multidrug resistance,
showing resistance to six non-b-lactam agents (erythro-
mycin, clindamycin, kanamycin, streptomycin, chloram-
phenicol, and tetracycline),5 while M013 lacks the MESPM1
sequence, containing only IS1216V at the chromosomal att
site (in the sasK gene).17 In terms of drug resistance, M013
is similar to a minor strain (PM18) of the Taiwan CA-MRSA
clone, which is susceptible to non-b-lactam agents, and
found in approximately 4.2% of Taiwan CA-MRSA isolates.5
For M013, no information is available for plasmids.17
KS1 and PM1 shared the same genetic characteristics,
except for SCCmec and ampicillin and tetracycline resis-
tance (encoded by a plasmid). As suggested previously,19
KS1, which lacks the marker genes (sep and sak) of phage
3, could be an ancestral strain of the Taiwan CA-MRSA
clone. Due to the MESPM1 structure, KS1, similar to PM1,
shows the constitutive phenotype of resistance to clinda-
mycin, a first-line agent for osteomyelitis.
As for virulence factors, those of USA300 have been
predicted to be PVL, which disrupts human phagocytes,
such as polymorphonuclear neutrophils; colonization fac-
tors encoded for by ACME; a-hemolysin (Hla), which plays a
role in necrotizing pneumonia; and PSMs (with high
expression levels), which play a role in bacteremia and
abscess formation.3
In terms of virulence factors, KS1 is characterized by
PVL, PSMs (with high expression levels), and SEB. PVL was
initially noted as a virulence factor of deep skin infections
572 E. Sawanobori et al.with large abscesses, such as furuncles and cellulitis,40,41
and has increasingly been noted in association with osteo-
myelitis.33,42 PVL enhances the severity of osteomyelitis in
a rabbit model.43 Moreover, a combination of PVL, protein
A, and Coa plays a role in bone loss and bone destruction in
osteomyelitis.44 Moreover, PVL seems to act as an MRSA
spread factor, allowing wide transmission through skin-to-
skin contact, by the secretion of MRSA in pus on the body
surface.4,45
SEB (a superantigen) is associated with pediatric osteo-
lyelitis46 and is the second most prevalent toxin in osteo-
myelitis.42 SEB is also an immune evasion factor in
staphylococcal infections.47
The high expression of PSMs is a common characteristic
of CA-MRSA.2,48 In addition to their possible role as viru-
lence factors as mentioned above, it was proposed that
truncated PSMs contribute to CA-MRSA niche establishment
on the skin (spread in the population).48 Indeed, both PVLþ
SCCmecV CA-MRSA (Taiwan clone) and Taiwanese PVL-
SCCmecIV CA-MRSA expressed the psma and hld genes at
high levels. CA-MSSA KS1 also exhibited high psma and hld
gene expression levels.
Since PVL is considered to be a marker of CA-MRSA, we
also analyzed the PSM expression levels of other PVLþ MSSA
strains and demonstrated that the expression levels of PVLþ
MSSA strains were significantly higher than those of PVL-
MSSA strains (isolated in hospitals).
Taken together, it is suggested that PVL and PSMs (with
high expression levels) contribute to S. aureus spread,
niche formation, and SSTI (such as furuncles) in the com-
munity, and that PVL, PSMs (with high expression levels),
and SEB contribute to the pathogenesis of invasive in-
fections, for example, bloodstream infection, osteomye-
litis, and pulmonary embolism for KS1. Further studies are
needed to clarify the virulence ability, associated with
osteomyelitis and pulmonary embolism, of the Taiwan CA-
MRSA clone and related ST59 CA-MSSA.Conflicts of interest
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